Altered TERT promoter and other genomic regulatory elements: occurrence and impact
暂无分享,去创建一个
[1] D. Schadendorf,et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. , 2014, Journal of the National Cancer Institute.
[2] A. Dobrovic,et al. Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies , 2016, Oncotarget.
[3] D. Schadendorf,et al. Analysis of SDHD promoter mutations in various types of melanoma , 2015, Oncotarget.
[4] Margaret Robertson,et al. Identification and characterization of the familial adenomatous polyposis coli gene , 1991, Cell.
[5] R. Young,et al. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL , 2017, Leukemia.
[6] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[7] Nam Huh,et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway , 2015, Nature Genetics.
[8] Jun S. Song,et al. Understanding TERT Promoter Mutations: A Common Path to Immortality , 2016, Molecular Cancer Research.
[9] K. Kinzler,et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. , 2013, Cancer research.
[10] C. Copie-Bergman,et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. , 2015, Blood.
[11] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[12] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[13] F. Izzo,et al. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma , 2016, Oncotarget.
[14] C. Larsson,et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas , 2014, Oncogene.
[15] J. Calderaro,et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.
[16] Miguel Melo,et al. Frequency of TERT promoter mutations in human cancers , 2013, Nature Communications.
[17] K. Hoang-Xuan,et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations , 2014, British Journal of Cancer.
[18] C. Bassing,et al. Genomic Alterations of Non-Coding Regions Underlie Human Cancer: Lessons from T-ALL. , 2016, Trends in molecular medicine.
[19] W. Chng,et al. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas , 2016, Proceedings of the National Academy of Sciences.
[20] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[21] Y. Jeng,et al. TERT promoter mutation is uncommon in acral lentiginous melanoma , 2014, Journal of cutaneous pathology.
[22] S. Hinrichs,et al. Structural evidence for the authenticity of the human retinoblastoma gene. , 1987, Science.
[23] Douglas F Easton,et al. Genome-wide association studies in common cancers--what have we learnt? , 2010, Current opinion in genetics & development.
[24] S. Boulton,et al. Molecular basis of telomere dysfunction in human genetic diseases , 2015, Nature Structural &Molecular Biology.
[25] D. Schadendorf,et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas , 2014, Modern Pathology.
[26] E. Zwarthoff,et al. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. , 2014, Investigative ophthalmology & visual science.
[27] Miguel Manzanares,et al. Allelic Variation at the 8q23.3 Colorectal Cancer Risk Locus Functions as a Cis-Acting Regulator of EIF3H , 2010, PLoS genetics.
[28] Len A. Pennacchio,et al. Enhancer Variants Synergistically Drive Dysfunction of a Gene Regulatory Network In Hirschsprung Disease , 2016, Cell.
[29] Nazneen Rahman,et al. Realizing the promise of cancer predisposition genes , 2014, Nature.
[30] B. Ponder,et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.
[31] Stephen C. J. Parker,et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants , 2013, Proceedings of the National Academy of Sciences.
[32] Michael C. Heinold,et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing , 2015, Nature Communications.
[33] C. Sander,et al. Genome-wide analysis of non-coding regulatory mutations in cancer , 2014, Nature Genetics.
[34] K. Brown,et al. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations , 2016, Proteomics.
[35] Xueda Hu,et al. Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas , 2014, International journal of cancer.
[36] Michael R. Green,et al. Transcriptional regulatory elements in the human genome. , 2006, Annual review of genomics and human genetics.
[37] Andrew C. Wood,et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism , 2015, Nature.
[38] Stephen C. J. Parker,et al. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma , 2013, Proceedings of the National Academy of Sciences.
[39] Jesse R. Dixon,et al. Topological Domains in Mammalian Genomes Identified by Analysis of Chromatin Interactions , 2012, Nature.
[40] B. Vogelstein,et al. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers , 2015, Genes & development.
[41] C. Carlson,et al. Principles for the post-GWAS functional characterization of cancer risk loci , 2011, Nature Genetics.
[42] J. Bishop,et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] David C. Jones,et al. Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.
[44] K. Hemminki,et al. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences , 2015, Oncotarget.
[45] P. Hou,et al. Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers , 2014, International journal of cancer.
[46] D. Bardin. On the ? - ? interaction , 1970 .
[47] John L Hopper,et al. Multiple loci with different cancer specificities within the 8q24 gene desert. , 2008, Journal of the National Cancer Institute.
[48] B. Deplancke,et al. The Genetics of Transcription Factor DNA Binding Variation , 2016, Cell.
[49] D. Reich,et al. Functional Enhancers at the Gene-Poor 8q24 Cancer-Linked Locus , 2009, PLoS genetics.
[50] E. Campo. MYC in DLBCL: partners matter. , 2015, Blood.
[51] P. Rothberg,et al. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma , 2014, Modern Pathology.
[52] S. Kyo,et al. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers , 2008, Cancer science.
[53] R. Ren,et al. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.
[54] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[55] C. Larsson,et al. TERT promoter mutations and gene amplification: Promoting TERT expression in Merkel cell carcinoma , 2014, Oncotarget.
[56] R. C. Poulos,et al. Systematic Screening of Promoter Regions Pinpoints Functional Cis-Regulatory Mutations in a Cutaneous Melanoma Genome , 2015, Molecular Cancer Research.
[57] Dorota H. Sendorek,et al. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer , 2016, Nature Genetics.
[58] Shane J. Neph,et al. Personal and population genomics of human regulatory variation , 2012, Genome research.
[59] M. Gerstein,et al. Role of non-coding sequence variants in cancer , 2016, Nature Reviews Genetics.
[60] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[61] E. Larsson,et al. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types , 2014, Nature Genetics.
[62] J. Bishop,et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. , 2013, Endocrine-related cancer.
[63] Mathieu Lupien,et al. Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. , 2016, Cancer discovery.
[64] Sandra Krüger,et al. Melanomas of unknown primary frequently harbor TERT-promoter mutations , 2014, Melanoma research.
[65] David T. W. Jones,et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.
[66] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[67] K. Hemminki,et al. TERT promoter mutations in cancer development. , 2014, Current opinion in genetics & development.
[68] M. Beckmann,et al. An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. , 2016, Human molecular genetics.
[69] D. Schadendorf,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .
[70] Z. Cai,et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. , 2014, European urology.
[71] M. Fullwood,et al. Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation. , 2016, Cancer discovery.
[72] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[73] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[74] J. Llovet,et al. TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma. , 2014, Journal of hepatology.
[75] P. Kleihues,et al. TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.
[76] A. Nussenzweig,et al. End-joining, translocations and cancer , 2013, Nature Reviews Cancer.
[77] Shane J. Neph,et al. Systematic Localization of Common Disease-Associated Variation in Regulatory DNA , 2012, Science.
[78] ENCODEConsortium,et al. An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.
[79] Gary D Bader,et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma , 2014, Nature.
[80] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[81] D. Schadendorf,et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours , 2013, British Journal of Cancer.
[82] Christopher A. Haiman,et al. The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer , 2009, Nature Genetics.
[83] Britta A. M. Bouwman,et al. A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia , 2014, Cell.
[84] Functional analysis of CDKN2A/p16INK4a 5'-UTR variants predisposing to melanoma. , 2010, Human molecular genetics.
[85] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[86] Stephen J. Chanock,et al. Current status of genome-wide association studies in cancer , 2011, Human Genetics.
[87] R. Young,et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element , 2014, Science.
[88] V. Tergaonkar,et al. Telomerase: central regulator of all of the hallmarks of cancer. , 2013, Trends in biochemical sciences.
[89] James C. Costello,et al. TERT promoter mutations and telomerase reactivation in urothelial cancer , 2015, Science.
[90] J. Boyle,et al. Cancer-associated TERT promoter mutations abrogate telomerase silencing , 2015, eLife.
[91] T. Chan,et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. , 2013, The Journal of clinical endocrinology and metabolism.
[92] L. Aaltonen,et al. Lessons from functional analysis of genome-wide association studies. , 2013, Cancer research.
[93] Rajiv Kumar,et al. TERT promoter mutations in telomere biology. , 2017, Mutation research.
[94] C. Liu,et al. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR , 2014, Oncotarget.
[95] D. Schadendorf,et al. TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.
[96] Adam G Diehl,et al. Deciphering ENCODE. , 2016, Trends in genetics : TIG.
[97] Ivana V. Yang,et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. , 2011, The New England journal of medicine.
[98] Paolo Vineis,et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types , 2009, Nature Genetics.
[99] Nazneen Rahman,et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene , 2011, Nature.
[100] Esko Ukkonen,et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling , 2009, Nature Genetics.
[101] Deqing Hu,et al. Enhancer malfunction in cancer. , 2014, Molecular cell.
[102] J. Ju,et al. A frequent somatic mutation in CD274 3′‐UTR leads to protein over‐expression in gastric cancer by disrupting miR‐570 binding , 2012, Human mutation.
[103] K. Dutton-Regester,et al. A highly recurrent RPS27 5'UTR mutation in melanoma , 2014, Oncotarget.
[104] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[105] I. Noth,et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. , 2013, JAMA.
[106] J. Becker,et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma , 2014, Nature Communications.
[107] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[108] J. Taipale,et al. The role of enhancers in cancer , 2016, Nature Reviews Cancer.
[109] Rajiv Kumar,et al. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation , 2016, Oncotarget.
[110] S. Tuft,et al. Autosomal-Dominant Corneal Endothelial Dystrophies CHED1 and PPCD1 Are Allelic Disorders Caused by Non-coding Mutations in the Promoter of OVOL2 , 2015, American journal of human genetics.
[111] Dawei Xu,et al. Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications , 2016, Genes.
[112] Marc A. Beal,et al. Whole genome sequencing for quantifying germline mutation frequency in humans and model species: cautious optimism. , 2012, Mutation research.
[113] L. Aaltonen,et al. Mice Lacking a Myc Enhancer That Includes Human SNP rs6983267 Are Resistant to Intestinal Tumors , 2012, Science.
[114] Darell D. Bigner,et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas , 2014, Oncotarget.
[115] W. Kim,et al. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population. , 2016, Thyroid : official journal of the American Thyroid Association.
[116] D. Schadendorf,et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism , 2013, Proceedings of the National Academy of Sciences.
[117] Keith A. Boroevich,et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity , 2015, Nature Communications.
[118] Jessica Zucman-Rossi,et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. , 2014, Cancer cell.
[119] D. Schadendorf,et al. High TERT promoter mutation frequency in non‐acral cutaneous metastatic melanoma , 2016, Pigment cell & melanoma research.
[120] J. Fallon,et al. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites. , 2015, Annals of diagnostic pathology.
[121] N. Hayward,et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.
[122] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[123] B. Necela,et al. Clinical and molecular features of Hürthle cell carcinoma of the thyroid. , 2015, The Journal of clinical endocrinology and metabolism.
[124] R. Dummer,et al. The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.
[125] Th. Boveri. Concerning the Origin of Malignant Tumours by Theodor Boveri. Translated and annotated by Henry Harris , 2008, Journal of Cell Science.
[126] A. Nordheim,et al. Frequent DPH3 promoter mutations in skin cancers , 2015, Oncotarget.
[127] D. Schadendorf,et al. TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma , 2013, PloS one.
[128] M. Tucker,et al. Germline splicing mutations of CDKN2A predispose to melanoma , 2003, Oncogene.
[129] M. Blasco,et al. Replicating through telomeres: a means to an end. , 2015, Trends in biochemical sciences.
[130] J. A. Bishop,et al. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. , 2001, Human molecular genetics.
[131] Marc Fellous,et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome , 1997, Nature Genetics.
[132] Keith A. Boroevich,et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer , 2016, Nature Genetics.
[133] V. Corces,et al. Enhancer function: new insights into the regulation of tissue-specific gene expression , 2011, Nature Reviews Genetics.
[134] Deng Cai,et al. Recurrent TERT promoter mutations in non-small cell lung cancers. , 2014, Lung cancer.
[135] Chibo Hong,et al. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer , 2015, Science.
[136] Nicholas A. Sinnott-Armstrong,et al. Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer , 2016, Nature Genetics.
[137] Niko Välimäki,et al. CTCF/cohesin-binding sites are frequently mutated in cancer , 2015, Nature Genetics.
[138] Steven J. M. Jones,et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.
[139] P. Chandrasekharan,et al. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation , 2015, Nature Cell Biology.
[140] A. Valencia,et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.
[141] M. Deininger,et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia , 2012, Nature Reviews Cancer.
[142] M. Honavar,et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. , 2014, The Journal of investigative dermatology.
[143] E. Grice,et al. Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability. , 2010, American journal of human genetics.
[144] K. Hemminki,et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer , 2015, International journal of cancer.